Clinical Trials/NCT01511900

NCT01511900

Completed

Phase 1

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAT-1004 in Patients With Type 2 Diabetes

Catabasis Pharmaceuticals0 sites44 target enrollmentDecember 2011

ConditionsType 2 Diabetes

InterventionsCAT 1004 Placebo

DrugsCAT 1004 Placebo

Overview

Phase: Phase 1
Intervention: CAT 1004
Conditions: Type 2 Diabetes
Sponsor: Catabasis Pharmaceuticals
Enrollment: 44
Primary Endpoint: Frequency and severity of adverse events
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The primary objective of the study is to evaluate the safety of escalating multiple doses over 2 weeks of CAT 1004 compared to placebo in patients with Type 2 diabetes (T2D).

Secondary objectives include evaluation of the pharmacokinetics (PK) and pharmacodynamics of escalating multiple doses of CAT-1004 in patients with T2D.

Registry

clinicaltrials.gov

Start Date

December 2011

End Date

April 2012

Last Updated

13 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Catabasis Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•A patient must meet all of the following criteria to be in the study:
•Age between 18 to 65 years inclusive at Screening.
•Diagnosis of T2D:
•For Part I:
•Treated with any diet and exercise, with or without metformin (stable for ≥ 2 months).
•HbA1c ≥ 7.0% and ≤ 10.0% if on diet and exercise alone, or ≥6.5 % and ≤ 9.0% if on metformin.
•For Part II:
•Stable on metformin for ≥ 2 months with HbA1c ≥ 7.0% and ≤ 10.0%.
•Satisfies one of the following:
•Females not of childbearing potential: non-pregnant and non-lactating; surgically sterile or postmenopausal for 2 years or at least 1 year with a follicle stimulating hormone assessment (FSH) greater than or equal to 40 IU/L; OR

Exclusion Criteria

•A patient will not be eligible if any of the following criteria apply:
•Use of prescription medications other than allowed medications within 30 days of planned admission to the clinic. Allowed medications include metformin, anti-hypertensives, lipid-lowering medications, thyroid replacement therapy, low-dose aspirin (81 mg/day), proton pump inhibitors and anti-depressants. Prescribed doses of these medications must have been stable for 2 months at the time of first dose.
•Clinically significant abnormalities in physical examination or vital signs at screening
•Clinically significant electrocardiogram (ECG) abnormalities as assessed by the investigator.
•Clinically significant laboratory result as assessed by the Investigator.
•The patient has a history of clinically significant medical disease including significant allergies (except for untreated, asymptomatic seasonal allergies at the time of dosing), or hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease, other than T2D, hypertension, dyslipidemia, hypothyroidism or depression.
•History or presence of malignancy within the past 5 years.
•History of Type 1 diabetes or clinically significant cardiovascular disease (including a history of unstable angina, acute myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, or New York Heart Association Class III or IV congestive heart failure within 6 months prior to screening) or clinically significant renal disease.
•History of alcohol or substance abuse or eating disorder within 2 years, OR regular use of alcohol within 6 months (\>14 units of alcohol per week; 1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).
•Use of any investigational drug or participation in any investigational study within 30 days prior to screening or 5 half-lives of the study agent, whichever is longer.

Arms & Interventions

Cohort 1: Dose level 1

Multiple dose orally: CAT-1004 Dose level 1 or placebo

Intervention: CAT 1004

Cohort 1: Dose level 1

Multiple dose orally: CAT-1004 Dose level 1 or placebo

Intervention: Placebo

Cohort 2: Dose level 2

Multiple dose orally: CAT-1004 Dose level 2 or placebo

Intervention: Placebo

Cohort 2: Dose level 2

Multiple dose orally: CAT-1004 Dose level 2 or placebo

Intervention: CAT 1004

Cohort 3: Dose level 3

Multiple dose orally: CAT-1004 Dose level 3 or placebo

Intervention: Placebo

Cohort 3: Dose level 3

Multiple dose orally: CAT-1004 Dose level 3 or placebo

Intervention: CAT 1004

Cohort 4: Dose level 4

Multiple dose orally: CAT-1004 Dose level 4 or placebo

Intervention: Placebo

Cohort 4: Dose level 4

Multiple dose orally: CAT-1004 Dose level 4 or placebo

Intervention: CAT 1004

Cohort 5: Dose level TBD

Multiple dose orally: CAT-1004 Dose level TBD or placebo

Intervention: Placebo

Cohort 5: Dose level TBD

Multiple dose orally: CAT-1004 Dose level TBD or placebo

Intervention: CAT 1004

Outcomes

Primary Outcomes

Frequency and severity of adverse events

Time Frame: Screening to Follow-up (Day 25)

Secondary Outcomes

Cmax of CAT-1004(Days 1, 7 and 14)
Glucose area under the curve for 0-24 hrs/24 and 0-4 hrs/4(Day -2 through f/u (Day 25))
Changes from baseline for hematology, chemistry, coagulation and urinalysis(Baseline through End of study (Day 25))
Changes from baseline in vital signs(Baseline through end of study (Day 25))
Changes from baseline for ECGs(Baseline through end of study (Day 25))
AUCinf of CAT-1004(Days 1, 7 and 14)
Changes from baseline for Physical exams(Baseline through end of study (Day 25))